Australija - engleski - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - amoxicillin trihydrate, quantity: 575 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: propylene glycol; magnesium stearate; croscarmellose sodium; dichloromethane; purified talc; microcrystalline cellulose; ethylcellulose; hypromellose; isopropyl alcohol; titanium dioxide; hyprolose; industrial methylated spirit - amoxyclav generichealth 500/125 and amoxyclav generichealth 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - amoxicillin trihydrate, quantity: 1006.25 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: purified talc; propylene glycol; isopropyl alcohol; hypromellose; ethylcellulose; croscarmellose sodium; dichloromethane; microcrystalline cellulose; magnesium stearate; titanium dioxide; hyprolose; industrial methylated spirit - amoxyclav generichealth 500/125 and amoxyclav generichealth 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - amoxicillin trihydrate, quantity: 575 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; isopropyl alcohol; microcrystalline cellulose; propylene glycol; purified talc; dichloromethane; hypromellose; ethylcellulose; magnesium stearate; titanium dioxide; hyprolose; industrial methylated spirit - apo-amoxy/clav 500/125 and apo-amoxy/clav 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg); amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate type a; dichloromethane; isopropyl alcohol; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - clavam tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to clavam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to clavam tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg); amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; isopropyl alcohol; magnesium stearate; dichloromethane; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - clavamox tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to clavamox tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to clavamox tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg); amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; dichloromethane; sodium starch glycollate type a; isopropyl alcohol; magnesium stearate; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - pharmaclav tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to pharmaclav tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to pharmaclav tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg); amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; dichloromethane; isopropyl alcohol; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - pharmacor moxclav tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to pharmacor moxclav tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to pharmacor moxclav tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.c

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanic acid (unii: 23521w1s24) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 400 mg in 5 ml -        to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium powder for oral suspension, usp (amoxicillin/clavulanate potassium) and other antibacterial drugs, amoxicillin and clavulanate potassium powder for oral suspension, usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.       amoxicillin and clavulanate potassium powder for oral suspension, usp is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: - caused by beta-lactamase-producing isolates of

Armenija - engleski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sandoz gmbh - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - powder for oral suspension - 125mg/5ml+ 31,25mg/5ml

Armenija - engleski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sandoz gmbh - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - powder for oral suspension - 250mg/5ml+ 62,5mg/5ml